ライフサイエンスコーパス: orphanin FQ

1 Microinjections of orphanin FQ (0.1-100 nmol) failed to produce conditioned

2 , enkephalins (100-1000 nmol) and nociceptin-orphanin FQ (3-30 nmol) only inhibit pain without elicit

3 Intracerebroventricular administration of Orphanin FQ (5.5, 55 or 550 pmol) caused a dose-related

4 stion, we focus here on the newly discovered Orphanin FQ, a peptide homologous to the opioid peptide

5 peptide that resembles dynorphin, was named 'orphanin FQ' and 'nociceptin' (OFQ/N1-17).The OFQ/N1-17

6 with very high affinity and yet still binds Orphanin FQ as well as the wild-type receptor.

7 phanin receptor mRNA expression with that of orphanin FQ binding at the ORL1 receptor in the adult ra

8 toward the Orphanin FQ receptor; conversely, Orphanin FQ has no affinity toward any of the opioid rec

9 Orphanin FQ-immunoreactive (OFQ-IR) neurons and nerve fi

10 A and binding supports an extensive role for orphanin FQ in a multitude of CNS functions, including m

11 istress systems (neuropeptide Y, nociceptin [orphanin FQ]) in drug dependence, with emphasis on the n

12 Nociceptin/orphanin FQ is a recently discovered neuropeptide and th

13 Nociceptin (Orphanin FQ) is a newly discovered endogenous heptadecap

14 Thus, it appears that orphanin FQ lacks motivational effects when administered

15 tems have attracted interest, the nociceptin/orphanin FQ (N/OFQ) and orexin/hypocretin (Orx/Hcrt) sys

16 Although nociceptin/orphanin FQ (N/OFQ) influences dopamine (DA) neuronal ac

17 Nociceptin/Orphanin FQ (N/OFQ) is an endogenous ligand of the N/OFQ

18 Nociceptin/orphanin FQ (N/OFQ) is an endogenous ligand of the ORL1

19 Nociceptin/orphanin FQ (N/OFQ) is the endogenous ligand for the N/O

20 The nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor is the fourth

21 europsychiatric disorders and the nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor.

22 vely and heterologously expressed nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptors with voltage

23 teria in the 1970s and 1980s, the nociceptin/orphanin FQ (N/OFQ) peptide receptor (NOP, also known as

24 ppa opioid agonists as well as nociceptin or orphanin FQ (N/OFQ) peptide, an endogenous ligand for an

25 led receptor whose natural ligand is the NOP/orphanin FQ (N/OFQ) peptide.

26 the hypocretin/orexin (Hcrt) and nociceptin/orphanin FQ (N/OFQ) peptidergic systems in the regulatio

27 mediator of stress responses, and nociceptin/orphanin FQ (N/OFQ) plays an important role in the modul

28 we evaluated whether blockade of nociceptin/orphanin FQ (N/OFQ) tone potentiated the antiparkinsonia

29 product of the same precursor as nociceptin/orphanin FQ (N/OFQ), has been shown to antagonize effect

30 stigated whether the neuropeptide nociceptin/orphanin FQ (N/OFQ), previously implicated in the pathog

31 Nociceptin/orphanin FQ (N/OFQ), the endogenous agonist for the opio

32 Since its discovery, the nociceptin/orphanin FQ (N/OFQ)-NOP receptor system has been extensi

33 gically active conformation(s) of nociceptin/orphanin FQ (N/OFQ).

34 The opiate-like peptide nociceptin/orphanin FQ (Noc) and its receptor [opiate receptor-like

35 on to the newly described opioid, nociceptin/orphanin FQ (NOC/oFQ) following hypoxia/ischemia in newb

36 ole of the newly described opioid nociceptin orphanin FQ (NOC/oFQ) in such impaired dilation to other

37 Nociceptin/orphanin FQ (NOC/oFQ) is a recently discovered endogenou

38 ion of the newly described opioid nociceptin orphanin FQ (NOC/oFQ) to hypoxic-ischemic impairment of

39 on to the newly described opioid, nociceptin/orphanin FQ (NOC/oFQ), following hypoxia/ischemia in new

40 e CSF concentration of the opioid nociceptin/orphanin FQ (NOC/oFQ), which contributes to impairment o

41 tropin-releasing factor (CRF) and nociceptin/orphanin FQ (nociceptin) regulate ethanol intake and anx

42 l addiction-related processes and nociceptin/orphanin FQ (nociceptin) regulates ethanol intake and an

43 Opioid peptides and nociceptin/orphanin FQ (nociceptin) within the CeA are implicated a

44 enous ligand for the orphan opioid receptor, orphanin FQ/nociceptin (OFQ), has recently been characte

45 de (U-69593) and the orphan receptor agonist orphanin FQ/nociceptin (OFQ).

46 The opioid peptide, Orphanin FQ/nociceptin (OFQ/N(1-17))(,) its active fragm

47 Orphanin FQ/nociceptin (OFQ/N) and its receptor (ORL-1)

48 Orphanin FQ/nociceptin (OFQ/N) and its receptor share su

49 Orphanin FQ/nociceptin (OFQ/N) suppresses the activity o

50 The heptadecapeptide, orphanin FQ/nociceptin (OFQ/N), binds with high affinity

51 Orphanin FQ/nociceptin (OFQ/N), the endogenous ligand fo

52 ss of D(2) receptors also potentiated spinal orphanin FQ/nociceptin analgesia.

53 Because the ORL-1 receptor agonist orphanin FQ/nociceptin blocks opioid-induced antinocicep

54 Unlike mice, orphanin FQ/nociceptin fails to elicit hyperalgesia in t

55 agenic studies to the exclusion of mammalian orphanin FQ/nociceptin from classic opioid ligands (i.e.

56 When administered intracerebroventricularly, orphanin FQ/nociceptin produces hyperalgesia and/or reve

57 id receptors and the ORL-1 receptor agonist, orphanin FQ/nociceptin, induces analgesia at the spinal

58 phincter of Oddi (SO) were immunostained for orphanin FQ/nociceptin.

59 hybridization studies revealed expression of orphanin-FQ/nociceptin (OFQ/N) receptor (NOR) mRNA in th

60 The nociceptin/orphanin FQ (NOP) receptor, the fourth member of the opi

61 Nociceptin/orphanin FQ (NOP/OFQ) is the endogenous ligand for the N

62 neurons showed that dopamine, baclofen, and orphanin FQ (OFQ) cause varying degrees of hyperpolariza

63 Orphanin FQ (OFQ) is a recently discovered neuropeptide

64 Orphanin FQ (OFQ) is the endogenous agonist of the opioi

65 While the influence of orphanin FQ (OFQ) on the regulation of food intake has b

66 We have previously shown that orphanin FQ (OFQ) preferentially stimulates muscle contr

67 of opioid receptor-like 1 receptor (ORL1) by orphanin FQ (OFQ) produces sex-specific modulation of sp

68 eceptor-ligand binding studies of the cloned orphanin FQ (OFQ) receptor suggest that multiple forms o

69 ntly isolated endogenous opioid-like peptide orphanin FQ (OFQ) was measured in two classical bioassay

70 The recently discovered neuropeptide orphanin FQ (OFQ), and its opioid receptor-like (ORL1) r

71 he endogenous opiate receptor-like 1 ligand, orphanin FQ (OFQ), which structurally resembles dynorphi

72 ce preparation, we have examined opioid- and orphanin FQ (OFQ)-mediated modulation of synaptic transm

73 The distributions of orphanin FQ (OFQ/N; also known as nociceptin) and its co

74 The effects of nociceptin (orphanin FQ) on medial vestibular nucleus (MVN) neurons

75 colocalization with MCH neurons: nociceptin/orphanin FQ opioid receptor (NOP), MCHR1, both orexin re

76 e examine biased signaling at the nociceptin/orphanin FQ opioid receptor (NOPR), the most recently id

77 The heptadecapeptide orphanin FQ or nociceptin (OFQ/N), the endogenous ligand

78 activation of the adrenergic and nociceptin/orphanin FQ peptide (NOP) opioid receptors, respectively

79 ith mixed mu opioid peptide (MOP)/nociceptin-orphanin FQ peptide (NOP) receptor agonist activity to a

80 Nociceptin/orphanin FQ peptide (NOP) receptor is a new class of opi

81 er nociceptin, which binds to the nociceptin/orphanin FQ peptide (NOP) receptor, is a core component

82 OP-1A), a new radioligand for the nociceptin/orphanin FQ peptide (NOP) receptor, with high affinity (

83 nd 4.1 nM, respectively) at human nociceptin/orphanin FQ peptide (NOP) receptors.

84 y agonists to delta-opioid (DOR), nociceptin/orphanin FQ peptide (NOPr), alpha2-adrenergic (alpha2AR)

85 ctivities at the kappa opioid and nociceptin/orphanin FQ peptide receptors.

86 ormones, pro-opiomelanocortin (POMC) and pro-orphanin FQ (pOFQ)/nociceptin (N), in the brain.

87 ne whether the newly-identified neuropeptide orphanin FQ produced motivational effects after intracer

88 t the fourth opioid receptor, the nociceptin/orphanin FQ receptor (NOP).

89 lts indicate that 1) several residues in the orphanin FQ receptor are critical to its selectivity aga

90 icinal chemists in designing ligands for the orphanin FQ receptor based on the structure of the opiat

91 This suggests that the Orphanin FQ receptor has developed features that specifi

92 Furthermore, the orphanin FQ receptor mutant that has the best affinities

93 These orphanin FQ receptor mutants also display stereospecific

94 After two rounds of mutagenesis, several orphanin FQ receptor mutants can be labeled with the opi

95 namics, morphine metabolites, the nociceptin/orphanin FQ receptor system, acute opioid tolerance and

96 aimed at shifting the binding profile of the orphanin FQ receptor toward that of the opioid receptors

97 by attempting to reverse it and endowing the Orphanin FQ receptor with the ability to bind opioids.

98 xyl-terminal regulation of NOPR (nociceptin, orphanin FQ receptor) signaling and function.

99 oid peptide Dynorphin, and its receptor, the Orphanin FQ receptor, which is highly homologous to the

100 ively low affinity or no affinity toward the Orphanin FQ receptor; conversely, Orphanin FQ has no aff

101 High affinity and saturable nociceptin (orphanin FQ) receptors were detected and characterized i

102 here is little direct cross-talk between the Orphanin FQ system and the endogenous opioid system.

103 (ORL1) and its endogenous ligand nociceptin/orphanin FQ, which displayed anti-opioid properties, has